Table 1 Clinical-pathological characteristics of MpBC among (neo) adjuvant CT or no CT groups.
From: Chemotherapy is of prognostic significance to metaplastic breast cancer
| Â | Neoadjuvant CT | Adjuvant CT | No CT | P | |||
|---|---|---|---|---|---|---|---|
No | % | No | % | No | % | ||
Year of diagnosis | |||||||
 2010–2011 | 34 | 18.8% | 140 | 21.6% | 93 | 26.0% | 0.286 |
 2012–2013 | 38 | 21.0% | 157 | 24.3% | 82 | 22.9% | |
 2014–2015 | 44 | 24.3% | 161 | 24.9% | 87 | 24.3% | |
 2016–2017 | 65 | 35.9% | 189 | 29.2% | 96 | 26.8% | |
Age | |||||||
  ≤ 60 | 124 | 68.5% | 354 | 54.7% | 86 | 24.0% |  < 0.001 |
  > 60 | 57 | 31.5% | 293 | 45.3% | 272 | 76.0% | |
Race | |||||||
 White | 131 | 72.4% | 486 | 75.1% | 299 | 83.5% | 0.009 |
 Black | 35 | 19.3% | 112 | 17.3% | 36 | 10.1% | |
 Others* | 15 | 8.3% | 49 | 7.6% | 23 | 6.4% | |
Histology | |||||||
 Others | 22 | 12.2% | 67 | 10.4% | 74 | 20.7% |  < 0.001 |
 NST | 159 | 87.8% | 580 | 89.6% | 284 | 79.3% | |
Histologic grade | |||||||
 I | 1 | 0.6% | 18 | 2.8% | 35 | 9.8% |  < 0.001 |
 II | 20 | 11.0% | 74 | 11.4% | 60 | 16.8% | |
 III | 160 | 88.4% | 555 | 85.8% | 263 | 73.5% | |
Stage | |||||||
 I | 7 | 3.9% | 181 | 28.0% | 115 | 32.1% |  < 0.001 |
 IIA | 60 | 33.1% | 306 | 47.3% | 146 | 40.8% | |
 IIB | 48 | 26.5% | 102 | 15.8% | 63 | 17.6% | |
 IIIA | 31 | 17.1% | 33 | 5.1% | 11 | 3.1% | |
 IIIB | 28 | 15.5% | 21 | 3.2% | 17 | 4.7% | |
 IIIC | 7 | 3.9% | 4 | 0.6% | 6 | 1.7% | |
T | |||||||
 T1 | 13 | 7.2% | 196 | 30.3% | 120 | 33.5% |  < 0.001 |
 T2 | 84 | 46.4% | 362 | 56.0% | 159 | 44.4% | |
 T3 | 54 | 29.8% | 68 | 10.5% | 60 | 16.8% | |
 T4a–c | 26 | 14.4% | 20 | 3.1% | 17 | 4.7% | |
 T4d | 4 | 2.2% | 1 | 0.2% | 2 | 0.6% | |
N | |||||||
 N0 | 101 | 55.8% | 529 | 81.8% | 324 | 90.5% |  < 0.001 |
 N1 | 53 | 29.3% | 95 | 14.7% | 22 | 6.1% | |
 N2 | 20 | 11.0% | 19 | 2.9% | 6 | 1.7% | |
 N3 | 7 | 3.9% | 4 | 0.6% | 6 | 1.7% | |
Surgery | |||||||
 BCS | 52 | 28.7% | 331 | 51.2% | 161 | 45.0% |  < 0.001 |
 Mastectomy | 129 | 71.3% | 316 | 48.8% | 197 | 55.0% | |
Radiation therapy | |||||||
 Yes | 126 | 69.6% | 350 | 54.1% | 120 | 33.5% |  < 0.001 |
 No or unknown | 55 | 30.4% | 297 | 45.9% | 238 | 66.5% | |
ER | |||||||
 Positive | 51 | 28.2% | 119 | 18.4% | 60 | 16.8% | 0.004 |
 Negative | 130 | 71.8% | 528 | 81.6% | 298 | 83.2% | 0.004 |
PR | |||||||
 Positive | 31 | 17.1% | 76 | 11.7% | 40 | 11.2% | 0.107 |
 Negative | 150 | 82.9% | 571 | 88.3% | 318 | 88.8% | |
HER2 | |||||||
 Positive | 17 | 9.4% | 40 | 6.2% | 11 | 3.1% | 0.009 |
 Negative | 164 | 90.6% | 607 | 93.8% | 347 | 96.9% | |
Subtype | |||||||
 HR + /HER2– | 52 | 28.7% | 147 | 22.7% | 75 | 20.9% | 0.003 |
 HR + /HER2 +  | 8 | 4.4% | 11 | 1.7% | 2 | 0.6% | |
 HR–/HER2 +  | 9 | 5.0% | 29 | 4.5% | 9 | 2.5% | |
 TNBC | 112 | 61.9% | 460 | 71.1% | 272 | 76.0% | |
Response to NAC | |||||||
 CR | 22 | 12.2% | – | – | – | – |  |
 PR | 67 | 37.0% | – | – | – | – |  |
 CR or PR | 48 | 26.5% | – | – | – | – |  |
 No response | 44 | 24.3% | – | – | – | – |  |
